Reference
Medicines and Healthcare products Regulatory Agency (UK). Carfilzomib (Kyprolis): reminder of risk of potentially fatal cardiac events. Drug Safety Update 13: 6-7, No. 1, Aug 2019. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/826120/Aug-2019-PDF.pdf
Rights and permissions
About this article
Cite this article
Risk of potentially fatal cardiac events with carfilzomib. Reactions Weekly 1768, 6 (2019). https://doi.org/10.1007/s40278-019-66691-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-66691-3